1. In Vivo
  2. >>Global Vision

Merger Rumors for Japan's Drug Firms

Shionoghi and Sumitomo Pharmaceuticals are both facing big cuts in revenues as American and European partners take back marketing rights to major products. Sumitomo Bank, a major shareholder and debtholder in both, is likely to try to put the two companies together.

Can Japanese drug companies survive as independents? Japan’s lifetime employment traditions makes restructuring tough in any event, though companies are downsizing through attrition. Takeda, for example, apparently intends to decrease its total employment by 20%, largely through attrition.

But Japanese companies have been reluctant to move more aggressively—unless they are forced to do so.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.